Thursday, March 4, 2021

Moderna vaccine gives at least 3 months’ immunity, study shows

Experts say it is very likely that the immune system will remember the virus if re-exposed later on, and then produce new antibodies.

Other News

Australia’s Qantas launches ‘mystery flights’ to boost domestic tourism

From today, passengers can book flights departing from Brisbane, Sydney or Melbourne, without knowing their destination.

Just the ticket – Moscow Metro to bring in FacePay system this year

Similar systems are already in place in some Chinese cities.

Time to be honest about crossing the aisle

Elected representatives should be held to the same standards when it comes to party-hopping, regardless of political affiliation.

Dua maut, tiga parah dalam runtuhan jejambat di MRR2

kesemua mangsa adalah warga tempatan berusia dalam lingkungan 30 hingga 45 tahun.

SpaceX rocket explodes on ground after seemingly successful flight

The rocket exploded a few minutes after landing and was thrown into the air following which it crashed back to the ground.

The Moderna Covid-19 vaccine, which the company says was recently demonstrated to have 94% efficacy, causes the human immune system to produce potent antibodies that endure for at least three months, a study showed Thursday.

Researchers at the National Institute for Allergies and Infectious Diseases (NIAID), which co-developed the drug, studied the immune response of 34 adult participants, young and old, from the first stage of a clinical trial.

Writing in the New England Journal of Medicine, they said that the antibodies, which stop the SARS-CoV-2 virus from invading human cells, “declined slightly over time, as expected, but they remained elevated in all participants three months after the booster vaccination”.

The vaccine, called mRNA-1273, is administered in two injections given 28 days apart.

Even though the number of antibodies in the study subjects faded over time, it is not necessarily a cause for concern.

NIAID director Anthony Fauci and other experts have said it is very likely that the immune system will remember the virus if re-exposed later on, and then produce new antibodies.

Encouragingly, the study showed that the vaccine activated a certain type of immune cell that should help out in the so-called memory response, but only longer term study will confirm if this will really be the case.

“Positives from the study include evidence that a relatively strong antibody response remains 90 days after the second dose of the vaccine,” said virologist Benjamin Neuman, a virologist at Texas A&M University-Texarkana.

“The amount of vaccine-produced antibodies was higher in younger patients than in older patients, but reasonably strong immune responses were still seen even in patients up to 70 years of age.”

The Moderna vaccine will be reviewed by an advisory committee of the Food and Drug Administration (FDA) on Dec 17, and could be green lit for emergency approval soon after.

Like another vaccine produced by Pfizer and BioNTech, it is based on a new technology that uses genetic material in the form of mRNA (messenger ribonucleic acid).

The mRNA is encased in a lipid molecule and injected into the arm, where it causes cells inside our muscles to build a surface protein of the coronavirus.

This tricks the immune system into believing it’s been infected with a microbe, and trains it to build the right kind of antibodies for when it encounters the real virus.

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

Brazil reports second straight day of record Covid-19 deaths

Far-right President Jair Bolsonaro faces sharp criticism for downplaying the new coronavirus, flouting expert advice on containing it with lockdowns and face masks, and over his government's slow pace in vaccinating the population.

AstraZeneca vaccine effective in over-80s, study shows

Stephen Evans, professor of Pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, says the results 'provide further evidence that the vaccines are effective both in an older age group less studied in the trials'.

India developer says homegrown Covid-19 vaccine is 81% effective

Questions had been raised about the effectiveness of Bharat Biotech's Covaxin after officials authorised it for emergency use in January even though its Phase 3 trials were not complete.

Sweden sees first case of baby infected with Covid-19 in the womb

The baby was also found to have developed its own antibodies against the virus.